![]() |
|
|
Departments of
Drug Metabolism (C.P., A.K., W.A.) and
Medicinal
Chemistry (H.H.), Central Research Division, Pfizer Inc.
The metabolism and excretion of ziprasidone
(5-[2-{4-(1,2-benzisothiazol-3-yl)piperazin-1-yl}ethyl]-6-chloroindolin-2-one hydrochloride hydrate) were studied in Long Evans rats after oral administration of a single dose of a mixture of
14C- and 3H-labeled
ziprasidone. The radioactive dose was quantitatively recovered over 7 days in both male and female rats. The percentage of the dose excreted
in urine, bile, and feces of rats was 21.6, 19.2, and 55.6%,
respectively. The total excretion in urine and bile suggested that at
least 41% of the drug was absorbed. Absorption of ziprasidone was
rapid, and the mean plasma concentrations of the unchanged drug and
metabolites were slightly higher in the female rats than in the males.
The maximal plasma concentrations for ziprasidone and metabolites were
reached at 1 hr in both male and female rats. Based on AUC (0-12 hr)
values, approximately 59 and 52% of the circulating radioactivity
(average of 14C and 3H)
was attributable to metabolites in male and female rats, respectively. Ziprasidone was extensively metabolized in rats, and only a small amount of ziprasidone was excreted as unchanged drug. Twelve
metabolites were identified by ion spray LC/MS, using a combination of
parent ion and product ion scanning techniques. The structures of eight metabolites were unambiguously confirmed by coelution on HPLC with
synthetic standards, and four additional metabolites were partially
identified. There was a gender-related difference in the excretion of
urinary metabolites in Long Evans rats. The major route of metabolism
in male rats involved N-dealkylation. In female rats
the major metabolites were due to oxidation at the benzisothiazole ring. Based on the structures of these metabolites, four major and two
minor routes of metabolism of ziprasidone were identified. The major
routes included 1) N-dealkylation of the ethyl side chain attached to the piperazinyl nitrogen, 2) oxidation at the sulfur,
resulting in the formation of sulfoxide and sulfone, 3) oxidation on
the benzisothiazole moiety (other than sulfur), and 4) hydration of the
C
N bond and subsequent oxidation at the sulfur of the
benzisothiazole moiety. The minor routes involved
N-oxidation on the piperazine ring and hydrolysis of the
oxindole moiety.
This article has been cited by other articles:
![]() |
Z. Miao, A. Kamel, and C. Prakash CHARACTERIZATION OF A NOVEL METABOLITE INTERMEDIATE OF ZIPRASIDONE IN HEPATIC CYTOSOLIC FRACTIONS OF RAT, DOG, AND HUMAN BY ESI-MS/MS, HYDROGEN/DEUTERIUM EXCHANGE, AND CHEMICAL DERIVATIZATION Drug Metab. Dispos., July 1, 2005; 33(7): 879 - 883. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Tschirret-Guth and H. B. Wood SUBSTITUENT EFFECT ON THE REDUCTIVE N-DEARYLATION OF 3-(INDOL-1-YL)-1,2-BENZISOXAZOLES BY RAT LIVER MICROSOMES Drug Metab. Dispos., August 1, 2003; 31(8): 999 - 1004. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Prakash and V. Soliman Metabolism and Excretion of a Novel Antianxiety Drug Candidate, CP-93,393, in Long Evans Rats. Differentiation of regioisomeric glucuronides by LC/MS/MS Drug Metab. Dispos., November 1, 1997; 25(11): 1288 - 1297. [Abstract] [Full Text] |
||||
![]() |
C. Prakash, A. Kamel, J. Gummerus, and K. Wilner Metabolism and Excretion of a New Antipsychotic Drug, Ziprasidone, in Humans Drug Metab. Dispos., July 1, 1997; 25(7): 863 - 0. [Abstract] [Full Text] |
||||
![]() |
C. Prakash, A. Kamel, and D. Cui Characterization of the Novel Benzisothiazole Ring-Cleaved Products of the Antipsychotic Drug Ziprasidone Drug Metab. Dispos., July 1, 1997; 25(7): 897 - 901. [Abstract] [Full Text] |
||||